Scrip 100: Has novelty in the depression pipeline hit a wall?
This article was originally published in Scrip
Executive Summary
The health of the depression pipeline was brought into question in early 2014 when Shire's Vyvanse (lisdexamfetamine dimesylate) failed in Phase III, becoming just another product to fall at the final development hurdles for major depressive disorder (MDD).